Navigation Links
Omeros Commences Initial Public Offering of Common Stock
Date:9/18/2009

ne at (800)-503-4611 or by email: prospectusrequest@list.db.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery((TM)) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery((TM)) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-looking Statements

This press release contains "forward-lo
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
2. Omeros Appoints New Vice President of Clinical Development
3. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. Omeros and BlueCrest Announce $20 Million Debt Facility
6. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
7. Omeros Appoints David A. Mann to its Board of Directors
8. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
9. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
10. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
11. PCI Biotech Commences Phase I/II Trials of Amphinex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... LABS, Inc., a global, full-service testing laboratory with more ... human organs, cells, tissues and implantable biologic products and ... top private companies, as judged by the annual ... The Top 250 Private Companies list is an annual ...
... Biolabs (NEB), in its continuing commitment to open access ... covering DNA polymerase biochemistry, genetics and structural biology. Inspired ... maintained by NEB), Polbase summarizes the information that exists ... easy for researchers to interrogate and use. Polbase can ...
... Wolters Kluwer Pharma Solutions, a leading provider of ... and analytics to investors through Bloomberg Tradebook,s Independent Research ... in Thought™, Wolters Kluwer Pharma ... analyses of pharmaceutical drugs and medical devices. ...
Cached Biology Technology:LABS, Inc. Among Colorado's Top Private Companies 2New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers 2Wolters Kluwer Research Now Available via Bloomberg Tradebook 2Wolters Kluwer Research Now Available via Bloomberg Tradebook 3
(Date:4/18/2014)... sprout as soon as they,re planted may be good news ... careful. In the wild, a plant whose seeds sprouted at ... More than just an insurance policy against late frosts or ... long-term advantages too: Plants whose seeds put off sprouting ... finds in a team of researchers working at the National ...
(Date:4/18/2014)... Calif. A team of researchers led by ... been selected to receive a $7.5 million Department of ... simple and basic scientific foundations for the predictable design ... a wide diversity of structures from plants and animals, ... are taking what biological systems have constructed over millions ...
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Multitarget TB drug could treat other diseases, evade resistance 2
... Duke University study suggests that evolution can behave as ... on an energy-efficient style of four-footed running over long ... evolved a profoundly inefficient gait, tailor-made to creep up ... "It is usually assumed that efficiency is what matters ...
... problem of children failing to take their medication for ... as part of a new university research project. ... of Nottingham and The University of Leicester will draw ... congenital heart disease and epilepsy to learn about the ...
... Deerfield, IL, December 3, 2008 Today, the International ... professional organization of stem cell researchers, released new guidelines ... cell therapies for patients. A Commentary article that summarizes ... will be published by Cell Press in the December ...
Cached Biology News:Dogs chase efficiently, but cats skulk counterintuitively 2A spoonful of sugar? 2A spoonful of sugar? 3The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
... peptide derived from an internal region of ... of rapamycin FRAP RAFT1 RAPT1). Specificity: ... On Western blots it identifies the target ... (positive control: HEK293 cell lysates). Based on ...
Biology Products: